MFO is actually related to a lower CD36 content or lower CS activity (Maunder et al., 2022), intimately linked to atherosclerotic processes (Tian et al., 2020) or tumor defense (Wang et al., 2020), as well as poorer physical performance (Maunder et al., 2022). Here, CD36 is linked to neoplasm.